MorphoSys : Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi
17/4 03:53
(RTTNews) - MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (MOR), and Incyte (INCY) announced final five-year follow-up data from the Phase 2 L-MIND study showing that Monjuvi (tafasitamab-cxix) plus lenalidomide followed by Monjuvi monotherapy provided prolonged,...